Albert Burdulis is a Strategy Advisor to the leadership team at Neuronoff, Inc.  

Al was the first hire at Spinal Modulation Inc. (SMI), the company that conceived and developed Dorsal Root Ganglion (DRG) stimulation from its inception. In his role as VP of Mechanical Systems at SMI, Al worked with all functional groups of the company (mechanical, electrical, software, firmware, drug), and managed the development of the mechanical design. His work included hardware, animal trials, as well as NSR study development at SMI. After successfully proving human DRG stimulation in a pivotal clinical trial, St. Jude Medical (SJM) purchased SMI for a combined sum of over $300 MM and Al helped with the integration of SMI into SJM. When Abbott acquired SJM a few years later for $23.5 Bn, Al once again helped with the integration of the team and the technology into the new parent company. 

Feeling the pull back towards the startup environment, Al eventually exited Abbott to join Autonomic Technologies Inc (ATI) as VP of R&D and Operations, a company focused on neurostimulation for cluster headache and migraine. When ATI had to restructure, Al left to join  InCube labs (Sacramed), a neuromodulation company for urinary incontinence, as VP of Engineering. In total, Al has 35+ years of medical start-up experience, 15 of which he spent in the neuromodulation space with 4 different companies prior to Neuronoff.

Al is providing strategic advice to R&D, Clinical, QA and others in the leadership team. He has been instrumental in verifying that Neuronoff’s device development is in alignment with verification and validation testing requirements. His extensive experience in preparation of documentation for regulatory approval enables Neuronoff to anticipate and better prepare for interactions on a national and international level.

Al holds a BSME in Mechanical Engineering, Bio-engineering from UC Santa Barbara.